

****Published September 2021****

MarketVIEW: Respiratory virus vaccines (CAT: VAMV085)

Product Name	:	MarketVIEW: Respiratory virus vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (>200 slides.pdf) + forecast workbook(s) (.xls)
Therapeutic Area	:	Respiratory virus vaccines
Publication date	:	September 2021
Catalogue No	:	VAMV085

Background

With the emergence of **COVID-19 [SARS-CoV-2]** global pandemic in early 2020, and the rapid development of new vaccines, **VacZine Analytics** believes the development of further respiratory virus vaccines has become more critical. Even before the pandemic, **lower respiratory tract infections (LRTIs)**, due to all causes, were a leading cause of morbidity and mortality globally with an estimated **2.3m deaths (GBD, 2016)**. LRTIs are the sixth leading cause of mortality worldwide (all ages) and the leading cause of death in children younger than 5 years (2018 figures). In the best case, the mortality exerted by LRTIs has doubled due to the **SARS-CoV-2 coronavirus pandemic** which has already caused ~4.6m deaths (CSSE, JHU as of 15th September 2021). Limiting future mortality is now critically dependent on the speed of deployment and the real-world effectiveness of global mass vaccination campaigns. Virological parameters, such as genetic variation, the duration of vaccine-induced immunity and impact on transmission are important (as yet undefined) variables.

This brand new 'investor style' **Respiratory virus vaccines report** looks collectively at this overall market segment and covers **7 important respiratory pathogens** including viruses such as seasonal influenza, Respiratory Syncytial Virus (RSV), SARS-CoV-2 [pandemic/seasonal], human metapneumovirus/PIV3 and others which will continue to dominate manufacturer R&D focus over the coming years. The report contains a comparative discussion of the global disease burden exerted by these pathogens, vaccine profiles (TPPs) with all relevant commercial assumptions, competitive dynamics and POS/Non-POS adjusted new vaccine revenue (\$ 000s) forecasts per region (USA and Major 5 EU) to 2035. **New product development** is a report focus with an emphasis on **mRNA candidates** and marketing strategy. It is an ideal analysis for those wishing to understand the key issues and longer-term outlook for this important vaccine market segment.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Respiratory virus vaccines in each respective market. Source materials used are academic literature articles, government websites, medical bodies and associations, conference proceedings, social media etc. Previously published research by **VacZine Analytics** in the field of viral respiratory pathogens has also been utilised.

PRODUCT CONTENTS:

Published September 2021 (CAT No: VAMV085)

****This product is a [summary presentation \(.pdf\)](#), [an MS-workbook \(.xls\)](#)

Contents – Summary presentation (.pdf)¹

Contents

Author's notes

Executive summary

[SECTION 1] Lower Respiratory Tract Infections: general overview

[SECTION 2] Comparing major respiratory viruses: virological parameters

[SECTION 3] Respiratory viruses segment – vaccines market potential

Existing sales of respiratory virus vaccines

Defining the respiratory virus vaccines market segment

Existing and new vaccines for respiratory viruses

Commercial assumptions for new respiratory virus vaccines

Market potential +5 yrs for respiratory virus vaccines

Volume potential + 5yrs for respiratory virus vaccines

Total USA+M5EU segment \$ forecast for respiratory virus vaccines to 2035 [POS/Non-POS]*

Total USA segment \$ forecast for respiratory virus vaccines to 2035

Total EU segment \$ forecast for respiratory virus vaccines to 2035

Total USA+M5EU \$ forecast for respiratory virus vaccines per pathogen to 2035

Total USA \$ forecast for respiratory virus vaccines per pathogen to 2035

Total EU \$ forecast for respiratory virus vaccines per pathogen to 2035

Total USA+M5EU segment vol forecast for respiratory virus vaccines to 2035

Total USA segment vol forecast for respiratory virus vaccines to 2035

Total EU segment vol forecast for respiratory virus vaccines to 2035

Total USA+M5EU vol forecast for respiratory virus vaccines per pathogen to 2035

Total USA vol forecast for respiratory virus vaccines per pathogen to 2035

Total EU vol forecast for respiratory virus vaccines per pathogen to 2035

[SECTION 4] Respiratory viruses – COVID19 [SARS-CoV-2]

[SECTION 5] Respiratory viruses – Human metapneumovirus/PIV3[^]

[SECTION 6] Respiratory viruses – Respiratory Syncytial Virus

[SECTION 7] Respiratory viruses – Human Rhinovirus (HRV)

[SECTION 8] Respiratory viruses – Seasonal influenza virus

[SECTION 9] Respiratory viruses – MERS-CoV

References/bibliography

About **VacZine Analytics**

Disclaimer

PAGES: >200 slides fully referenced/sourced. Available in .pdf form

**For all forecasts, ^parainfluenza virus*



SNAPSHOT

Sections 4-9 (where applicable) example contents are:
Pathogen/disease profile
Vaccine TPP
R&D status
Commercial forecasts (annotated)
Assumptions: pricing/coverage/launch etc

¹ The COVID-19 [SARS-CoV-2] section is kept 'live' where possible, the MS Workbook contains val/vol figures at Region and val at the country level

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$11,995.00**/ GBP **£8,695.00**# (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

- *indicative prevailing rate will be applied on date of transaction*

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.




VacZine Analytics © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics © and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

References – available upon request



TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased on line invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third-party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster including pandemic, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

A division of Assay Advantage Ltd
Warren (Carlton) House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 927049
E-mail: info@vaczine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics ® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics ® and "the spiral logo" are UK Registered Trademarks, 2009



Since 2007

